Direct answer. Heart disease during pregnancy includes conditions present before conception and problems first recognised during pregnancy or after birth. The diagnosis, current heart function and treatment matter more than the broad label. Assessment should involve maternity and cardiac expertise, with an individual medicine, birth and follow-up plan. New severe symptoms need urgent assessment rather than being assumed normal pregnancy changes. NHS coronary disease and pregnancy, May21,2024; NHS congenital heart disease and pregnancy, April29,2024.
- A childhood heart repair still matters when planning a pregnancy.
- Review heart medicines before conception or promptly when pregnancy is recognised.
- The safest birth plan depends on the condition; heart disease does not automatically require Caesarean delivery.
- New chest pain, severe breathlessness or fainting needs urgent assessment.
- Cardiac care and warning signs continue after the baby is born.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Does every heart condition carry the same pregnancy risk? | Clinical assessment | No. Anatomy, function, symptoms and current treatment change the discussion. |
| Does childhood surgery end the need for review? | Congenital-heart education | No. Reconnect with adult congenital expertise before conception or early in pregnancy. |
| Are all usual heart medicines suitable? | Medicine-safety context | No. Review the actual ingredients, indications and pregnancy/lactation stages. |
| Must delivery be by Caesarean? | Clinical planning | No automatic rule; an individual maternity/cardiac plan is needed. |
| Does delivery end cardiac risk? | Postpartum guidance | No. Ongoing symptoms and follow-up still matter. |
Confidence is high in the need for condition-specific assessment and urgent attention to warning signs; recommendations are attributed clinical context, not independently certified treatment effects. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Existing and newly recognised heart conditions
A person may enter pregnancy with congenital heart disease, coronary disease, a cardiomyopathy, valve disease, a rhythm disorder or another cardiovascular diagnosis. These conditions have different implications. A broad statement that “heart disease and pregnancy are safe” cannot account for those differences. NHS coronary disease and pregnancy, May21,2024.
Congenital heart disease means a structural problem present from birth. A repair in childhood may have changed circulation substantially, but the original anatomy, repair and present function remain relevant. If follow-up stopped years ago, tell the maternity team and seek adult congenital cardiac review. NHS congenital heart disease and pregnancy, April29,2024.
Some cardiovascular problems first become apparent during pregnancy or after delivery. Blood-pressure disorders and pregnancy-related cardiomyopathy are important examples. Symptoms can overlap with ordinary pregnancy experiences, which makes a change in severity or ability to function worth assessing. NHS high blood pressure in pregnancy, November13,2024; NHLBI peripartum cardiomyopathy, February4,2025.
Preconception assessment and the Pregnancy Heart Team
Pregnancy increases the work required of the heart and circulation. An existing condition may become more difficult to manage, or an undiagnosed condition may become apparent. This does not mean that pregnancy inevitably damages every person’s heart. The starting diagnosis and current assessment matter. NHS coronary disease and pregnancy, May21,2024.
Preconception assessment gives time to discuss the condition, medicines, possible interventions and practical care arrangements. If pregnancy is already established, contact the relevant teams promptly rather than assuming the opportunity for useful planning has passed. NHS coronary disease and pregnancy, May21,2024.
The2025 ESC guideline describes a Pregnancy Heart Team approach, shared decisions and care extending from planning through the postpartum period. Risk assessment is a clinical task; its categories are not a home calculator or a verdict on whether someone is allowed to become pregnant. Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193.
For congenital disease, ask whether specialist fetal cardiac assessment or genetic advice is appropriate. Not every congenital condition has the same inheritance pattern, and an affected parent does not automatically mean the baby has the same defect. NHS congenital heart disease and pregnancy, April29,2024.
Condition-specific treatment and birth planning
Treatment begins with identifying the condition and its present severity. Maternity and cardiac teams should agree who will coordinate care and where assessment or delivery can safely occur. Keep copies of the diagnosis, previous operations and current medicines available to the team. NHS congenital heart disease and pregnancy, April29,2024.
Blood pressure may have been elevated before conception or first rise during pregnancy. Routine checks matter because raised pressure may not cause obvious symptoms. Monitoring can include urine tests and assessment of the baby’s growth, according to the clinical situation. NHS high blood pressure in pregnancy, November13,2024.
Pre-eclampsia can affect several organs as well as the pregnancy. Clinicians assess the parent and baby, control blood pressure and decide whether hospital care, seizure prevention or delivery is needed. Diagnosis is not something to settle from a single symptom or one home urine result. NHS pre-eclampsia, March23,2026.
Pregnancy-related cardiomyopathy is a heart-muscle disorder associated with heart-failure symptoms, including breathlessness, marked fatigue and fluid accumulation. Assessment may involve echocardiography and blood tests. Treatment and any device decision require specialist review; this guide does not promise recovery or recommend an experimental medicine. NHLBI peripartum cardiomyopathy, February4,2025.
The guideline supports individualized birth planning; vaginal delivery is suitable for many patients, while some circumstances require a different approach. Caesarean delivery should not be treated as the automatic solution to every cardiac diagnosis. Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193.
Nutrition, supplements and appropriate activity
Nutrition should support the pregnancy rather than pursue an extreme “heart detox.” The NHS diet page describes a varied diet; its2023 review is overdue, so this guide uses the general principle rather than a fixed menu. Discuss restrictions, nausea or difficulty obtaining adequate food with the care team. NHS diet in pregnancy, April21,2023; review overdue.
Prenatal supplements have nutritional purposes. The current NHS source discusses folic acid, vitaminD and iron when appropriate, and warns against cod-liver oil or supplements containing retinol because excess vitaminA can harm development. These recommendations are not evidence that a supplement treats cardiomyopathy, coronary disease or pre-eclampsia. NHS pregnancy vitamins and supplements, June3,2026.
A prenatal product and a separate “heart” supplement can contain overlapping ingredients. Show the actual labels to a pharmacist or maternity clinician, especially when using several products. This guide has not independently established a cardiac supplement regimen for pregnancy.
General pregnancy exercise advice needs adapting when a heart condition is present. The NHS current page advises discussing activity with the maternity team where there are health problems. A population exercise target is not permission to exercise through chest pain, faintness or worsening breathlessness. NHS exercise in pregnancy, September24,2026.
Prevention, monitoring and evidence limits
The useful question is what a proposed intervention is intended to prevent or treat in this particular pregnancy. Monitoring, a medicine adjustment and a procedure solve different problems. Clinical recommendations are attributed here; the funding audit does not certify every underlying treatment trial as independent.
Low-dose aspirin may be prescribed after assessment of pre-eclampsia risk. The GSTT source describes this clinical pathway and flags bleeding history, ulcers and asthma for discussion. This is not advice for every pregnant reader to start aspirin. Local instructions about timing and duration must come from the team. GSTT selected aspirin prevention context, April2026 version3.
A reassuring earlier assessment does not explain every later symptom. Conversely, a difficult pregnancy history does not provide a complete prediction for the next pregnancy. Current cardiac findings and the proposed care plan need review. NHLBI peripartum cardiomyopathy, February4,2025.
Ask what is known, what remains uncertain and how a change in symptoms will be handled. A plan should be understandable enough to use at night or during a transfer of care, not just recorded as a risk category.
Urgent symptoms during pregnancy and after birth
Seek emergency help for chest pain, severe or worsening difficulty breathing, collapse or a racing heartbeat accompanied by faintness or breathlessness. Tell responders that you are pregnant or recently gave birth. A symptom checklist cannot rule out serious disease. CDC HEAR HER maternal warning signs, May15,2024; credits AIM.
Severe headache, visual changes, pain beneath the ribs, sudden face or hand swelling, or feeling very unwell during pregnancy or after birth needs urgent assessment for possible pre-eclampsia. The condition can cause serious complications; do not wait for the next routine appointment when these symptoms develop. NHS pre-eclampsia, March23,2026.
CDC maternal warnings also include one-sided painful leg swelling, heavy bleeding and thoughts of harming yourself or the baby. The warning period extends beyond hospital discharge, including the year after delivery. This is a reason to mention recent pregnancy when seeking care, not a claim that all such symptoms have a cardiac cause. CDC HEAR HER maternal warning signs, May15,2024; credits AIM.
New inability to lie flat comfortably, breathlessness that is escalating or fatigue that severely limits usual tasks deserves review. Cardiomyopathy symptoms may be mistaken for normal pregnancy changes. Avoid using an internet explanation to dismiss a clear deterioration. NHLBI peripartum cardiomyopathy, February4,2025.
Heart medicines in pregnancy and breastfeeding
Review every prescription, nonprescription medicine and supplement. Suitability depends on the actual drug, the reason it is needed and whether the person is pregnant, postpartum or breastfeeding. A whole medicine class cannot be cleared by the word “natural” or “commonly used.”
Ramipril is unsuitable during pregnancy and needs urgent prescriber contact and replacement planning. The NHS source explains concern about fetal kidney development. Do not postpone an ingredient-specific review until a routine later visit or improvise a replacement dose. NHS ramipril pregnancy and lactation, March18,2026.
Anticoagulants require specialist coordination. The NHS source advises contacting the prescribing or anticoagulant service when planning pregnancy or discovering it. Mechanical-valve anticoagulation is particularly complex: protecting the parent from valve thrombosis and considering fetal risks require an expert plan, not abrupt unsupervised withdrawal. NHS anticoagulant considerations, September9,2024; Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193.
The FDA removed its strongest blanket statin pregnancy warning in2021, while still advising that most pregnant patients discontinue statins under clinical care; selected very-high-risk circumstances need specialist judgment. That US safety action is not permission to start or continue a statin without review. Lactation advice also needs separate attention. FDA July20,2021 statin pregnancy/lactation regulatory safety communication.
Situations needing specialist counselling
Avoid using a generic article to decide that pregnancy is harmless or forbidden because of a diagnosis label. Very-high-risk situations need candid counselling, discussion of options and respect for the person’s decisions. The specialist guideline explicitly centres autonomy and shared decisions. Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193.
People with previous pregnancy-related cardiomyopathy need review before another pregnancy. Symptoms, recovery and current function affect the discussion. Recovery after a previous episode does not provide an unconditional guarantee for a future pregnancy. NHLBI peripartum cardiomyopathy, February4,2025.
Avoid self-starting aspirin, herbal remedies or supplements as prevention for a feared complication. A clinician may recommend a product for a defined indication, but that requires checking suitability and the current medicine list. GSTT selected aspirin prevention context, April2026 version3.
The written care plan and postpartum follow-up
This guide provides no personal doses, medicine substitutions, anticoagulation schedules or delivery dates. Ask for a written plan covering contact details, follow-up, medicine review and which changes need immediate assessment. Bring up practical barriers to appointments or obtaining medicines.
After delivery, blood pressure and other treatment may still need review. If breastfeeding is planned, check each medicine individually; suitability during pregnancy is not the same question as transfer into breastmilk. Tell the team if the baby is premature or unwell. NHS high blood pressure in pregnancy, November13,2024; NHS ramipril pregnancy and lactation, March18,2026.
Postpartum fluid and circulatory changes can affect heart conditions. Follow-up should be tailored rather than ending at birth. The guideline also treats adverse pregnancy outcomes as reasons to discuss longer-term cardiovascular health; an association does not prove that one pregnancy complication alone caused later disease. Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193.
Why laboratory findings do not establish pregnancy safety
Laboratory findings can suggest how pregnancy hormones or vessels interact with heart muscle; they cannot establish safe treatment for the pregnant person or baby. Animal and in-vitro findings are excluded from this guide’s clinical efficacy conclusions. Human drug evidence also needs ingredient-specific interpretation. A changed laboratory marker is different from a demonstrated benefit for survival, symptoms or infant development. Manufacturer-funded or supplied-product evidence is Tier4/GradeD for financial independence even when methods are strong.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 27 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Pregnancy Heart Team and medicine recommendations are attributed clinical context. National websites, separate provider institutions, regulators and professional societies have different financial routes. This review does not clear every underlying pregnancy intervention trial, establish a numerical prognosis or rank commercial therapies. Exact page allocations and complete author/trial chains remain unclosed.
The clinical subject has no single corporate owner; medicines, devices and supplements have separate commercial ownership and financial interests. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS coronary disease and pregnancy, May21,2024 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original body read, with selective use. Simplified pregnancy/medicine/activity generalizations or dated review limit inference; NHS diet review is overdue. Public education supports attributed context; no universal medicine safety, exercise clearance, delivery rule, diagnostic threshold or outcome number adopted. Full contributor/trial finances unclosed. Role: Existing or newly recognised coronary disease and preconception assessment. |
| NHS congenital heart disease and pregnancy, April29,2024 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original body read, with selective use. Simplified pregnancy/medicine/activity generalizations or dated review limit inference; NHS diet review is overdue. Public education supports attributed context; no universal medicine safety, exercise clearance, delivery rule, diagnostic threshold or outcome number adopted. Full contributor/trial finances unclosed. Role: Adult congenital review, repaired anatomy and individualized pregnancy/birth planning. |
| NHS high blood pressure in pregnancy, November13,2024 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original body read, with selective use. Simplified pregnancy/medicine/activity generalizations or dated review limit inference; NHS diet review is overdue. Public education supports attributed context; no universal medicine safety, exercise clearance, delivery rule, diagnostic threshold or outcome number adopted. Full contributor/trial finances unclosed. Role: Blood-pressure review, surveillance and postpartum medicine discussion; thresholds excluded. |
| NHS pre-eclampsia, March23,2026 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual dated original body read for selected clinical education. Public-care accountability/accuracy incentive; simplified national pathways and unclosed contributor/original-trial finance remain. No numerical outcomes, fixed doses, self-screening criteria or personal clearance. Role: Selected hypertensive-pregnancy complications, warning signs and monitoring. |
| NHLBI peripartum cardiomyopathy, February4,2025 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual February4,2025 body read. Public-education accuracy incentive; simplified timing, genetic/race associations, device/breastfeeding generalizations and original contributor/trial finances unresolved. Selected symptom, diagnostic and recurrent-pregnancy discussion only; population rates, universal wearable-device benefit and trial efficacy excluded. Role: Selected peripartum cardiomyopathy symptoms, assessment and future-pregnancy discussion. |
| CDC HEAR HER maternal warning signs, May15,2024; credits AIM | CDC public budget authority/public transfers: actualFY2026 operating plan. Separate gift policy permits gifts/in-kind/Foundation transfers; no named private donation is attributed to this page. Warning list credits AIM; exact page allocation, AIM contributor/backer chain and underlying studies remain unclosed. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 1 public education provisional; gift, donor and full page-specific chain unresolved. | B provisional — actualMay2024 warning-sign original read. Public-safety incentive; symptom list is not exhaustive or diagnostic. AIM collaboration and complete author/study funding not cleared. No reassurance from a negative checklist. Role: Maternal emergency recognition during pregnancy and year after delivery. |
| NHS ramipril pregnancy and lactation, March18,2026 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual dated original body read for selected clinical education. Public-care accountability/accuracy incentive; simplified national pathways and unclosed contributor/original-trial finance remain. No numerical outcomes, fixed doses, self-screening criteria or personal clearance. Role: Ingredient-specific pregnancy suitability and urgent prescriber review. |
| NHS anticoagulant considerations, September9,2024 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual dated original body read for selected clinical education. Public-care accountability/accuracy incentive; simplified national pathways and unclosed contributor/original-trial finance remain. No numerical outcomes, fixed doses, self-screening criteria or personal clearance. Role: Pregnancy/lactation anticoagulant review and interaction cautions. |
| FDA July20,2021 statin pregnancy/lactation regulatory safety communication | FDA public budget authority plus regulated-industry fees: actually checkedFY2026 operating plan drug-programme lines. Exact page allocation, individual reviewer interests and full original study/applicant chains unresolved; fees are not evidence a named company paid for this page. | United States; FDA White Oak, Silver Spring, Maryland, US regulatory jurisdiction. Original cited study jurisdictions and medicine manufacturing origins not fully traced. | Tier 2 regulator status/safety context; original study/author finances unclassified. | B provisional for the actual July20,2021 regulatory safety action, not individual pregnancy/lactation clearance. Public safety oversight supports scrutiny; dated jurisdiction-specific advice and financially unclosed observational/nonclinical studies remain. Role: Dated US statin pregnancy/lactation safety status; selected specialist exceptions. |
| NHS pregnancy vitamins and supplements, June3,2026 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual dated original body read for selected clinical education. Public-care accountability/accuracy incentive; simplified national pathways and unclosed contributor/original-trial finance remain. No numerical outcomes, fixed doses, self-screening criteria or personal clearance. Role: Nutritional indication and excess-vitaminA warning, not cardiac prevention efficacy. |
| NHS diet in pregnancy, April21,2023; review overdue | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original body read, with selective use. Simplified pregnancy/medicine/activity generalizations or dated review limit inference; NHS diet review is overdue. Public education supports attributed context; no universal medicine safety, exercise clearance, delivery rule, diagnostic threshold or outcome number adopted. Full contributor/trial finances unclosed. Role: Selected varied diet context; dated page, fixed menu excluded. |
| NHS exercise in pregnancy, September24,2026 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original body read, with selective use. Simplified pregnancy/medicine/activity generalizations or dated review limit inference; NHS diet review is overdue. Public education supports attributed context; no universal medicine safety, exercise clearance, delivery rule, diagnostic threshold or outcome number adopted. Full contributor/trial finances unclosed. Role: Current generic activity advice requires existing-heart-condition review. |
| GSTT selected aspirin prevention context, April2026 version3 | Separate GSTT provider; see own2025–26 NHS/private/research/charity/commercial financial profile. Exact leaflet allocation, authors and original aspirin-trial interests unclosed; national NHS-only finances do not substitute. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | C provisional — actualApril2026version3 original selected passages read. Specialist/public-care accuracy incentive plus local service and financially unresolved trial context. Selected clinician-assessed prevention, bleeding/asthma cautions and monitoring only; dose/start-stop schedules, benefit rates and broad medicine-safety reassurance excluded. Role: Selected clinician-assessed pre-eclampsia prevention context; regimen and efficacy excluded. |
| Guy’s and St Thomas’ audited2025–26 accounts | Guy’s and St Thomas’ NHS Foundation Trust: actual audited2025–26 accounts discloses NHS commissioners, private patients, research/education, charitable and commercial income. Actual institutional partnership names include Johnson & Johnson Managed Services, Diaverum and ActiveCareGroup; no attribution to this leaflet or complete contributor/trial chain established. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 3 institutional financial self-report. | B provisional — actual audited institutional report, no full individual allocation. Financial provenance only. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| FDA actualFY2026 budget authority and regulated-industry fee plan | FDA agency financing: actually checkedFY2026 operating plan distinguishes public budget authority and regulated-industry user fees, with drug programmes on printedp0 and devices onp2. Full page/application allocation, individual staff interests and exact fee-payer chain unclosed. This is aggregate agency funding, not proof a named company sponsored a safety page. | United States; FDA White Oak, Silver Spring, Maryland; US federal regulator. | Tier 3 agency financial/contact self-disclosure. | B provisional for explicit fiscal-year financing and actual headquarters contact. Statutory reporting and oversight improve checking; agency self-report, incomplete individual/page allocations and fee-payer chains remain. Provenance only. |
| FDA actual headquarters visitor/contact original | FDA agency financing: actually checkedFY2026 operating plan distinguishes public budget authority and regulated-industry user fees, with drug programmes on printedp0 and devices onp2. Full page/application allocation, individual staff interests and exact fee-payer chain unclosed. This is aggregate agency funding, not proof a named company sponsored a safety page. | United States; FDA White Oak, Silver Spring, Maryland; US federal regulator. | Tier 3 agency financial/contact self-disclosure. | B provisional for explicit fiscal-year financing and actual headquarters contact. Statutory reporting and oversight improve checking; agency self-report, incomplete individual/page allocations and fee-payer chains remain. Provenance only. |
| Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193 | Originalp8: ESC financed development, without healthcare-industry involvement. Separate ESC institutional income includes relevant life-science/medtech partnerships. Official author report was indexed but direct403; complete declarations and original-study financial chains were not retrieved. No particular company funding of this guideline is inferred. | France; ESC European Heart House, Sophia Antipolis; multinational professional guideline. Actual original mirrored by CPRV French clinical site; complete host ownership/backers and every author/study jurisdiction unclosed. | Tier 2 professional guidance with relevant institutional/author ties; original efficacy finance unclassified. | C provisional — actual full107-page original mirrored by French cardiology clinic CPRV, selected preamble/team/valve/postpartum/key-message sections read. Professional accuracy incentives; many clinical recommendations rest on limited evidence, separately from this independence grade. No independent efficacy certification, numerical outcomes, exact medicine or procedural criteria. Role: Selected actually read current pregnancy guideline framework. |
| ESC official2025 pregnancy guideline overview, August29,2025 | See actual guideline row for document-development finance and society institutional financial routes. Complete author declarations, original-trial chains and exact page allocations unclosed. Official indexed disclosures do not clear the full report or prove that a particular company financed this page. | France; ESC European Heart House, Sophia Antipolis; multinational professional guideline. Actual original mirrored by CPRV French clinical site; complete host ownership/backers and every author/study jurisdiction unclosed. | Tier 2 professional guidance with relevant institutional/author ties; original efficacy finance unclassified. | C provisional — actual officialAugust2025 overview read; scope/date and team/shared-decision framework only. Full clinical detail comes from separately read original mirror. Society educational/reputational and industry relationships remain. Role: Official guideline date and scope. |
| ESC official2025 pregnancy author report, indexed passages only; direct403 | See actual guideline row for document-development finance and society institutional financial routes. Complete author declarations, original-trial chains and exact page allocations unclosed. Official indexed disclosures do not clear the full report or prove that a particular company financed this page. | France; ESC European Heart House, Sophia Antipolis; multinational professional guideline. Actual original mirrored by CPRV French clinical site; complete host ownership/backers and every author/study jurisdiction unclosed. | Tier 3 professional/author interest self-disclosure, access-limited. | C provisional — indexed official passages name relevant drug/device relationships; direct report403, full declaration set not read. Disclosures identify potential interests, not proof of specific guideline sponsorship. Financial context only. |
| Official December24,2025 pregnancy correction, DOIehaf1011; indexed only, direct failed | See actual guideline row for document-development finance and society institutional financial routes. Complete author declarations, original-trial chains and exact page allocations unclosed. Official indexed disclosures do not clear the full report or prove that a particular company financed this page. | France; ESC European Heart House, Sophia Antipolis; multinational professional guideline. Actual original mirrored by CPRV French clinical site; complete host ownership/backers and every author/study jurisdiction unclosed. | Tier 3 publisher correction/status context, access-limited. | C provisional — official indexedDecember2025 correction found; direct original failed. Exact technical corrections are not used for patient instructions. No doses, radiation projections or corrected measurement thresholds reproduced. Access/status limitation only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| NHS anticoagulants versus antiplatelets, September 9, 2024 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual September 9, 2024 reviewed original opened. Public-care accountability and review dating support attributed medicine/safety education. Named contributor, exact page allocation and complete original-drug-trial finance unresolved; no independent comparative efficacy clearance. Doses and universal long-term schedules not adopted. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| CDC original FY2026 operating plan | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC dated2016 gift authority,2022 editorial review | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC actual Atlanta contact and public-site provenance | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
Frequently asked questions
Can pregnancy be considered after childhood heart surgery? Discuss the original anatomy, repair and present heart function with adult congenital expertise; childhood surgery is not automatic clearance.
Does heart disease mean a Caesarean birth? No automatic rule. The cardiac and maternity teams plan delivery according to the diagnosis, stability and obstetric situation.
Should I wait for a routine appointment after discovering pregnancy while taking heart medicines? Contact the prescribing or maternity team promptly. Some ingredients need urgent review and replacement planning.
Are symptoms after delivery still relevant? Yes. Cardiac problems and pre-eclampsia can be recognised postpartum; severe symptoms need urgent assessment.
Can prenatal vitamins prevent pregnancy heart disease? They have specific nutritional purposes; this guide does not establish them as treatment for cardiomyopathy or hypertensive complications.
Sources and funding notes
- NHS coronary disease and pregnancy, May21,2024 — Existing or newly recognised coronary disease and preconception assessment.
- NHS congenital heart disease and pregnancy, April29,2024 — Adult congenital review, repaired anatomy and individualized pregnancy/birth planning.
- NHS high blood pressure in pregnancy, November13,2024 — Blood-pressure review, surveillance and postpartum medicine discussion; thresholds excluded.
- NHS pre-eclampsia, March23,2026 — Selected hypertensive-pregnancy complications, warning signs and monitoring.
- NHLBI peripartum cardiomyopathy, February4,2025 — Selected peripartum cardiomyopathy symptoms, assessment and future-pregnancy discussion.
- CDC HEAR HER maternal warning signs, May15,2024; credits AIM — Maternal emergency recognition during pregnancy and year after delivery.
- NHS ramipril pregnancy and lactation, March18,2026 — Ingredient-specific pregnancy suitability and urgent prescriber review.
- NHS anticoagulant considerations, September9,2024 — Pregnancy/lactation anticoagulant review and interaction cautions.
- FDA July20,2021 statin pregnancy/lactation regulatory safety communication — Dated US statin pregnancy/lactation safety status; selected specialist exceptions.
- NHS pregnancy vitamins and supplements, June3,2026 — Nutritional indication and excess-vitaminA warning, not cardiac prevention efficacy.
- NHS diet in pregnancy, April21,2023; review overdue — Selected varied diet context; dated page, fixed menu excluded.
- NHS exercise in pregnancy, September24,2026 — Current generic activity advice requires existing-heart-condition review.
- GSTT selected aspirin prevention context, April2026 version3 — Selected clinician-assessed pre-eclampsia prevention context; regimen and efficacy excluded.
- Guy’s and St Thomas’ audited2025–26 accounts — Separate provider actual current financial provenance.
- NHS England actual audited2025–26 accounts — National website institutional financial provenance.
- FDA actualFY2026 budget authority and regulated-industry fee plan — Actual current FDA public and industry-fee financing.
- FDA actual headquarters visitor/contact original — FDA actual headquarters jurisdiction.
- Actual2025 ESC pregnancy guideline,107-page original mirrored by CPRV, DOIehaf193 — Selected actually read current pregnancy guideline framework.
- ESC official2025 pregnancy guideline overview, August29,2025 — Official guideline date and scope.
- ESC official2025 pregnancy author report, indexed passages only; direct403 — Indexed author-interest context with explicit full-access gap.
- Official December24,2025 pregnancy correction, DOIehaf1011; indexed only, direct failed — Indexed correction status, technical instructions excluded.
- ESC funding and revenue model — Actual separate society institutional income channels.
- ESC conflict management policy — Actual society interest-governance context; not proof all bias removed.
- NHS anticoagulants versus antiplatelets, September 9, 2024 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- CDC original FY2026 operating plan — Financial provenance only.
- CDC dated2016 gift authority,2022 editorial review — Financial provenance only.
- CDC actual Atlanta contact and public-site provenance — Financial provenance only.
The selected clinical originals and institutional financial sources were opened, with access-limited author reports and corrections identified explicitly. Actual dated NHS/NHLBI/CDC/GSTT clinical bodies and selected107-page ESC pregnancy original were read. National NHS, GSTT, CDC, NHLBI and FDA financial routes were checked separately. ESC author report and December2025 correction were available only as indexed official passages; direct access failed, so complete declarations/corrected technical instructions are not claimed. Fixed medicine, exercise, birth and monitoring schedules, numerical outcome rates and industry efficacy are excluded. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.